Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Condition: Prostate Cancer
MeSH terms: Prostatic Neoplasms
Intervention: Dasatinib; Leuprolide Acetate (LHRH Analogue); Radical Prostatectomy
Intervention description: Dasatinib 100 mg administered once daily per oral route for 28 consecutive days; Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).; Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
Intervention MeSH terms: Dasatinib; Leuprolide
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 1.0
Sex: Male
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk
      localized prostate cancer.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Clinical stage T1-T3a disease.

          -  Must be willing to have a tumor biopsy, if previous tumor tissue unavailable for tumor
             marker analysis.

          -  Kattan pre-operative nomogram-predicted (based on stage, Prostate Specific Antigen
             (PSA) and Gleason score) 5-year risk of recurrence-free survival of 80% or less

          -  Must be deemed eligible for radical prostatectomy.

          -  Must be willing to use an effective method of contraception (hormonal or barrier
             method of birth control; abstinence) from the time consent is signed until 6 weeks
             after treatment discontinuation.

          -  Written informed consent and HIPAA authorization for release of personal health
             information.

          -  Age > 18 years at the time of consent.

        Exclusion Criteria:

          -  No evidence of regional, lymph node or distant metastasis on clinical or radiological
             assessments. All baseline radiology studies must be performed within 28 days prior to
             registration for protocol therapy.

          -  No prior malignancy in the past 2 years except for basal cell and squamous cell
             carcinoma of the skin. Other cancers with low potential for metastasis, such as in
             situ cancers (e.g., Grade 1, TA TCC (low grade superficial bladder cancer), and
             colonic polyp with focus of adenocarcinoma) can be enrolled after approval from the
             Sponsor Investigator.

          -  No prior hormonal therapy with the exception of oral 5-alpha-reductase inhibitors
             (finasteride, dutasteride, etc.). Patients who have received prior oral anti-androgen
             therapies (bicalutamide, flutamide, nilutamide, etc.), prior LHRH agonist therapy
             (leuprolide, goserelin acetate, etc.), or prior orchiectomy are ineligible.

          -  No prior systemic chemotherapy or radiotherapy for prostate cancer is allowed.
             Transurethral resection of the prostate for benign prostatic hypertrophy (BPH) and
             oral alpha-blockers (terazosin, tamsulosin, doxazosin) are permitted.

          -  No history of hemorrhage or thrombotic events (cerebrovascular accident, deep vein
             thrombosis, pulmonary embolism, etc.) within 6 months prior to registration for
             protocol therapy.

          -  No history of diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

          -  No history of diagnosed acquired bleeding disorder within one year (e.g., acquired
             anti-factor VIII antibodies) of registration on protocol therapy.

          -  No history of ongoing or recent (≤ 3 months of registration on protocol therapy)
             significant gastrointestinal bleeding

          -  No ongoing anti-coagulation and/or anti-platelet therapies allowed.

          -  No unresolved pleural or pericardial effusion of any grade within 3 months of
             registration for protocol therapy.

          -  No uncontrolled angina, congestive heart failure or MI within 6 months prior to
             registration for protocol therapy.

          -  No diagnosed congenital long QT syndrome.

          -  No history of clinically significant ventricular arrhythmias (such as ventricular
             tachycardia, ventricular fibrillation, or Torsades de Pointes).

          -  No prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)

          -  Following medications must be discontinued at least 7 days prior to registration for
             protocol therapy and be withheld for the duration of dasatinib therapy:

          -  Drugs that are generally accepted to have a risk of causing Torsades de Pointes

          -  Patient must not be receiving any prohibited CYP3A4 inhibitors /inducers/ substrates

          -  Anti-coagulation and/or anti-platelet therapies - to avoid potential bleeding risks.

          -  No major surgical procedure, open biopsy, or significant trauma within 28 days prior
             to registration for protocol therapy.

          -  Ability to comply with study and/or follow-up procedures and requirements.

          -  No treatment with any investigational agent for any medical condition within 28 days
             prior to registration for protocol therapy.

          -  No clinically significant infections or any other condition which, in the
             investigator's opinion, deems the patient an unsuitable candidate to receive the study
             drug.

          -  Ability to take oral medication (dasatinib must be swallowed whole).

          -  No known history of hypokalemia that cannot be corrected prior to registration on
             protocol therapy.

          -  No known history of hypomagnesemia that cannot be corrected prior to registration on
             protocol therapy.